 NEW YORK, NY ACCESSWIRE July 17, 2020 The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly-traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. A class action has commenced on behalf of certain shareholders in CytomX Therapeutics, Inc. The filed complaint alleges that defendants made materially false andor misleading statements andor failed to disclose that: i CytomX had downplayed issues with CX-072s efficacy observed in the PROCLAIM-CX-072 clinical program; ii CytomX had similarly downplayed issues with CX-2009s efficacy and safety observed in the PROCLAIM-CX-2009 clinical program; and iii as a result, the Companys public statements were materially false and misleading at all relevant times. 